Recent findings have indicated that TAK‐242 dose‐dependently alleviated DSS‐induced colitis symptoms and colonic lesions by downregulating TLR4 and JAK2/STAT3 mRNA and protein expression and increasing JAK2/STAT3 phosphorylation.20 This evidence concerns the gene JAK2 and colitis.